BrilliA Inc. is a pioneering biotechnology firm focused on advancing skin health and regenerative medicine by developing innovative solutions for wound healing and enhancing patient quality of life. Leveraging cutting-edge proprietary technologies, BrilliA aims to address critical unmet medical needs in the healthcare sector. Committed to rigorous research and development, the company is strategically positioned to transform scientific breakthroughs into impactful therapeutic products, reinforcing its leadership in a dynamic and rapidly evolving market.